CD226 and neoplasm: Blocking of NK activating receptors (i.e., NKG2D and DNAM-1) reduced tumor killing efficacy of AlloHSC-iNKT cells (Figures 3F–3H and S1E–S1G), confirming their NK-activating-receptor-mediated tumor-targeting function.